T-cell acute lymphoblastic leukemia (T-ALL) has a poor prognosis derived from its genetic heterogeneity, which translates to a high chemoresistance. Recently, our workgroup designed thrombospondin-1-derived CD47 agonist peptides and demonstrated their ability to induce cell death in chronic lymphocytic leukemia. Encouraged by these promising results, we evaluated cell death induced by PKHB1 (the first- 
(HMGB1). 14, 15 Collectively, these DAMP recruit antigen-presenting cells (APC) to ICD sites and stimulate the uptake, processing, and presentation of dead-cell-associated antigens, resulting in an adaptive immune response. 1, [16] [17] [18] However, DAMP release is not sufficient to determine whether a molecule will induce ICD; thus, in vivo vaccination experiments are the gold standard to identify ICD inducers. 19, 20 A subset of chemotherapeutic agents including doxorubicin, mitoxantrone, oxaliplatin, bortezomib, cyclophosphamide, and anthracycline have the ability to trigger ICD, 18, 21 hence activating anticancer immune responses. 1 These drugs are used to treat different types of cancer, including hematological malignancies such as acute lymphoblastic leukemia (ALL).
Acute lymphoblastic leukemia is the most common type of childhood cancer, accounting for 80% of cases, and is the second most common acute leukemia in adults. [22] [23] [24] The 5-year survival rate in adults is about 30%-50% compared to 90% in children. [25] [26] [27] ALL can affect B cells (B-ALL) or T cells (T-ALL); T-ALL has a high risk of relapse as a result of acquired therapy resistance. 28 Chemoresistance is one of the most important reasons for failure in cancer treatments. Some cells are selected in a micro-evolutive process of survival after therapy induction, leading to the eventual relapse of nearly one case out of five. [29] [30] [31] Because treatment options are limited for these patients, their prognosis is poor. Thus, the development of new treatments able to stimulate the immune system, such as ICD-inducers, is important to fight chemoresistant malignancies.
CD47 is a potential therapeutic target for refractory hematological malignancies, by blocking its function using monoclonal antibodies 32 or by its activation with peptides. 33, 34 CD47 is a transmembrane protein expressed ubiquitously and reported to be overexpressed in different types of hematological malignancies, including ALL. 35 CD47 plays many biological functions as a result of its interaction with at least two major ligands: signal-regulatory protein alpha (SIRPα) and the extracellular matrix protein, thrombospondin-1 (TSP1). SIRPα is present in APC such as macrophages and dendritic cells (DC), with which it controls a "don't eat me" signal that regulates programmed cell removal. 36 TSP1 mediates cell adhesion, migration, proliferation and death. 37 Thus, CD47 appears as a promising therapeutic target addressed by many approaches: for example, blockade of CD47-SIRPα interaction by monoclonal antibodies mediates innate, 32 as well as adaptive, immune responses. 38 Additionally, treatment with an anti-CD47 monoclonal antibody (CC2C6) has shown to induce caspase-independent cell death in T-ALL cell lines. 39 More recently, CD47 activation by peptides derived from the C-terminal domain of TSP-1 induces a caspase-independent and calcium-dependent cell death in different cancer cell lines. 33, 34, 40, 41 Indeed, CD47 engagement to PKHB1, the first-described serumstable soluble CD47-agonist peptide, induced changes in ER morphology, CRT exposure, reactive oxygen species (ROS) production and dissipation of the mitochondrial membrane potential in cells from patients with CLL. 33 The present work is focused on determining whether PKHB1 is able to induce a selective ICD in T-ALL cell lines, while conserving the principal characteristics of CD47-mediated cell death.
| MATERIAL S AND ME THODS

| Blood and PBMC isolation
Peripheral blood was collected from 10 healthy volunteers after obtaining written informed consent. This study was approved by Island, NY, USA), and incubated at 37°C in a controlled humidified atmosphere with 5% CO 2 . Cell count was carried out using Trypan blue (0.4% Sigma-Aldrich), a Neubauer chamber and an optic microscope (Zeiss Primo Star) as proposed by the ATCC's standard protocols.
| Flow cytometry, cell death induction, and inhibition
Annexin 
| Complete blood count
Heparinized blood acquired from mice was assessed using the automatic Hematology Analyzer BC 7000 (KontroLab, Rome, Italy).
Blood smears were carried out and fixed with methanol, stained with Wright's, and observed under the microscope to carry out differential blood white cell counts.
| Calreticulin exposure
Next, 1 × 10 6 cells/mL were plated, treated with PKHB1, and incubated for 2 hours. Cells were harvested, washed, and stained with 
| Western blot
In a serum-free culture medium, 1 × 10 6 cells/mL were seeded and treated with PKHB1 (CC 50 
| ATP release assay
In this step, 1 × 10 6 cells/mL were treated with PKHB1 (CC 50 and CC 100 for each cell line) for 2 hours. Supernatants were used to assess extracellular ATP by a luciferase assay (ENLITEN kit, Promega,
Madison, WI, USA) following the manufacturer's instructions.
Bioluminescence was assessed in a microplate reader (Synergy HT, Software Gen5; BioTek, Winooski, VT, USA) at 560 nm.
| High-mobility group box 1 release assay
Supernatants of untreated and treated (PKHB1 CC 50 
| In vivo model
Six-to-eight-week-old BALB/c female mice were maintained in controlled environmental conditions (25°C and 12 hours light/dark cycle) and were supplied with rodent food LabDiet 5001 (LabDiet, St. Louis, MO, USA) and water ad libitum. 
| Prophylactic vaccinations
| Tumor establishment, drug administration and tumor measurement
Tumor was established by s. 
| Long-term memory assay
Mice in complete remission after PKHB1 treatment were rechallenged with 2 × 10 6 cells in 100 μL PBS into the opposite limb, and tumor volume was measured as described above.
| Histology and immunohistochemistry
Tissues and organs were obtained and fixed in 10% neutral formalin, embedded in paraffin, sectioned (5 μm thickness) and stained with H&E (Sigma-Aldrich). Histopathological analysis was done by an external veterinarian pathologist (National professional certificate 2593012).
Immunohistochemistry was done using CD4; MT310 sc-19641 and CD8; 32-M4 sc-1177 (Santa Cruz Biotechnology) primary antibodies, adding the universal biotinylated secondary antibody (VECTASTAIN Universal Quick HRP kit; Vector Laboratories, Burlingame, CA, USA)
following the manufacturer instructions, and developed with diaminobenzidine substrate (ImmPACT DAB; Vector Laboratories). Finally, hematoxylin-counterstained slides were coverslipped using resin as mounting solution and observed under the microscope.
| Statistical analysis
Mice were randomly assigned to different groups for all in vivo studies.
Experiments were repeated three independent times. Mann-Whitney test and two-tailed unpaired Student's t test were carried out using GraphPad Prism Software (San Diego CA, USA) and presented as mean value ± SD. Pvalues were considered significant as follows: P < .05; P < .01 and P < .001.
| RE SULTS
| CD47 agonist peptide PKHB1 induces cell death in human and murine tumor lymphoblastic T-cell lines
The thrombospondin-1 mimetic peptide PKHB1 has shown cytotoxicity in several neoplastic cell lines. 33, 34 However, its effects on human 
| PKHB1 prompts caspase-independent but calcium-dependent cell death with loss of mitochondrial membrane potential in CEM, MOLT-4 and L5178Y-R cells
Once we determined that PKHB1 induces quick phosphatidylserine exposure and plasma membrane permeability in T-ALL cell lines, we next assessed whether PKHB1-induced cell death in T-ALL cells shared the principal biochemical features previously described for CD47-mediated cell death; these include caspase independence, 43 Figure 4B ).
In addition, we carried out cell counts from lymphoid organs that belonged to control, PKHB1-treated or healthy mice. Noticeably, in PKHB1-treated mice, a significant increase in cell number of BM, spleen and thymus cells, and a significant decrease in cell number of lymph nodes were observed ( Figure 4C ). Moreover, cell number of the same organs in PKHB1-treated mice was similar to that of healthy mice. Additionally, the white blood cell (WBC) differential was carried out and showed no significant difference between healthy and PKHB1-treated mice, whereas untreated tumor-bearing mice presented a significant difference from the other two groups in all leukocyte types ( Figure 4D ). Altogether, the above suggests that PKHB1 improves the antitumor immune system of tumor-bearing mice and indicates possible participation of the immune system in complete tumor regression. 
| PKHB1 treatment induces DAMP exposure and release in T-ALL cells
Previous results showed that PKHB1 could be an ICD inducer; thus, we assessed the exposure and release of several DAMP in T-ALL cells. In Figure 5 , it can be observed that CEM, MOLT-4, and L5178Y-R cells incubated with the CC 50 of PKHB1 presented a significant increase in CRT exposure, analyzed by flow cytometry ( Figure 5A ), and confocal microscopy ( Figure 5B ).
Then, we measured the expression and release of HSP90, HSP70, CRT and HMGB1. The presence of these DAMP was determined by western blot in cellular lysates and supernatant of untreated cells and PKHB1-treated cells at CC 50 and CC 100 for each cell line tested. Figure 6A shows the decrease in the expression of HSP90, HSP70, CRT, and HMGB1 in cellular lysates of cells treated with PKHB1.
Conversely, expression of these DAMP increased in PKHB1-treated supernatants compared with the untreated cells ( Figure 6B ). These results indicate that PKHB1 treatment prompts the release of heatshock proteins, CRT, and HMGB1 to the extracellular medium.
As HMGB1 release was barely detected by western blot, an ELISA assay was carried out. HMGB1 release varied depending on the cell line studied and on the concentration of PKHB1 used. Using PKHB1 CC 100 , in CEM, MOLT-4 and L5178Y-R cell lines, HMGB1 release was sixfold, fourfold and twofold, respectively, compared to the untreated control, whereas using PKHB1 CC 50 , MOLT-4 cells HMGB1 release was eightfold with respect to the control ( Figure 7A ).
F I G U R E 6
Heat shock protein (HSP)90, HSP70, calreticulin (CRT) and high-mobility group box 1 (HMGB1) protein expression and release in response to treatment with PKHB1. Western blot and densitometry analyses were carried out using cellular lysates (A) or supernatants (B) of CEM, MOLT-4 and L5178Y-R cells untreated and treated with two concentrations of PKHB1. Loading controls, β-actin, and Ponceau red were used to determine densitometry analyses of relative protein expression. Results shown are representative of triplicates of at least three independent experiments. NS= Not significant
Another important indicator that immunogenic death is taking place is ATP-release. Therefore, a bioluminescence assay was carried out, finding that in supernatants of PKHB1-treated cells at CC 50 and CC 100 , the presence of ATP significantly increased ( Figure 7B ).
| PKHB1-treated cells as prophylactic vaccine prevented tumor establishment of L5178Y-R cells
Considering the previous data, noting that PKHB1 treatment induces ICD, the next step was to carry out a prophylactic vaccination, which is the gold standard to confirm whether PKHB1 treatment induced ICD 
| PKHB1-treatment induced long-term prevention of tumor establishment
Additionally, we assessed long-term tumor prevention in mice that presented complete tumor regression after PKHB1 treatment. In these experiments one out of six mice (≈17%) rechallenged with 2 × 10 6 L5178Y-R viable cells developed tumor, whereas in the naïve control group, six out of six (100%) presented tumor growth ( Figure 8C ). Survival percentage was graphed using Kaplan-Meier curve, where rechallenged mice showed 90% survival ( Figure 8D ).
| D ISCUSS I ON
There are few scientific reports on the use of synthetic peptides that can induce ICD. [45] [46] [47] Herein, we assessed the ability of PKHB1, the first serum-stable CD47-agonist peptide: (i) to induce selective cell death in T-ALL cells with conserved characteristics of CD47-mediated cell death; and (ii) to determine whether this type of cell death is immunogenic. We observed that PKHB1 induced death in CEM, MOLT-4, and L5178Y-R cells (Figure 1 ), in a fast caspaseindependent process that implicates phosphatidylserine exposure along with plasma membrane permeabilization, and loss of mitochondrial membrane potential ( Figure 2 ) that is selective for malignant cells (Figure 3 ). These features have largely implicated CD47-induced cell death. 33, 34, 39, 40, 44 In addition, we observed that calcium dependence for cell death induced by PKHB1 was conserved in T-ALL cells, as previously observed in CLL cells. F I G U R E 7 PKHB1 induces high-mobility group box 1 (HMGB1) and ATP release in CEM, MOLT-4 and L5178Y-R cell lines. Cells were treated with PKHB1 at CC 50 and CC 100 for 2 h, then 100 μL supernatant of each sample was taken to measure HMGB1 release by ELISA (A) or ATP release through bioluminescence detection (B). Charts shown are means (± SD) of triplicates of three independent experiments. NS= Not significant
Indeed, PKHB1 prompted DAMP exposure and release on T-ALL cells.
As CRT is one of the principal molecules necessary to determine that cell death is immunogenic, 6, 18 we demonstrated its exposure, by flow cytometry and confocal microscopy, on T-ALL after PKHB1 treatment ( Figure 5 ). Diverse studies in the immunology field highlight the importance of CRT exposure as an "eat me" signal 6, 15, 50, 51 that helps antigen uptake by APC by binding to low-density lipoprotein receptor-related protein 1 (LRP1). 7 There is a tight correlation between CRT and CD47 expression in cancer cells. 51 Indeed, recently, it was determined that treatment of breast cancer cell lines with thrombospondin-1 (TSP-1) promoted interaction of TSP-1 with CRT and CD47 and induced cell autophagy and tumor growth inhibition in xenografted mice. 52 These results support the idea that TSP-1 or peptides derived from TSP-1 can induce cell death through CD47 activation and its correlation with CRT exposure. Also, HSP70 and HSP90, HMGB1 and ATP were released by PKHB1 treatment on CEM, MOLT-4 and L5178Y-R cell lines (Figures 6,7) . Release of these molecules is involved in the activation of the immune system and induction of potent anticancer immunity. 17, 53, 54 However, DAMP release is not sufficient to ensure ICD induction, and in vivo vaccination is considered the gold standard. 1, 18, 21 Our in vivo assays showed that PKHB1 activates short-and long- 55 Similar results were obtained using doxorubicin in a mouse colon carcinoma (CT26) cell line. 42 The use of this vaccine helps to stimulate anticancer immunity through the maturation of DC and cytotoxic T-cell activation 56 as well as enhancing NK cytotoxic activity. 57 Immunotherapy is a promising treatment option against cancer, 58 using host immune defenses against cancer and seeking to endow cancer cells with immunogenicity. 59 The increased immunogenicity of tumor cells triggers antitumor immune responses that could offer long-term therapeutic effects. 1 The finding that certain drugs are able to induce the awakening of the immune response by releasing DAMP and generating ICD triggered investigations to look for these types of agent. 1, 42, 57, 60 Anthracyclines, platinum derivatives, alkylating agents, and proteasome inhibitors are chemotherapeutic drugs with large amounts of evidence for triggering ICD. 61 Other therapeutic modalities that show ICD induction are photodynamic therapy, 62 radiotherapy, 63 oncolytic viruses, 64, 65 high hydrostatic pressure, 66 and other phytochemical agents such as shikonin 67, 68 and capsaicin. 69, 70 Overall, our results highlight the advantages of the potential therapeutic use of targeting CD47 through peptide-based strategies, such as PKHB1, leading us to consider that this peptide could be used in other types of cancer. However, the molecular pathway by which PKHB1 induces this type of death through CD47 signaling remains unclear, as does whether this type of treatment could be used therapeutically. Therefore, we believe that CD47 agonist peptides deserve further investigation, which might lead to the possibility of being scaled in the near future to clinical phases.
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